Stada And Richter Launch Teriparatide Across Europe Following Forsteo Expiry

Stada and Gedeon Richter have launched their respective Movymia and Terrosa teriparatide biosimilars in Europe, with Stada eyeing 24 individual countries.

Europe
Stada and Richter are launching teriparatide across Europe • Source: Shutterstock

Stada and Gedeon Richter have announced the European launch of their teriparatide biosimilars, Movymia and Terrosa respectively, following the expiry of patent protection for Eli Lilly’s Forsteo original.

Stada said it was going to gradually launch Movymia “as a cost-effective alternative in 24 countries starting at the end...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By 

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

 
• By 

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

One Month Remains To Enter GGB Awards 2025

 
• By 

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By 

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

More from Products

One Month Remains To Enter GGB Awards 2025

 
• By 

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By 

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

Biocon Biologics’ Yesafili Approved And Ready To Launch In Canada

 

Canada will welcome its first Eylea off-patent rival in July, as Biocon Biologics celebrates the commercialization of its 10th biosimilar worldwide.